269 related articles for article (PubMed ID: 35679628)
21. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
Bedke J; Rini BI; Plimack ER; Stus V; Gafanov R; Waddell T; Nosov D; Pouliot F; Soulières D; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Tamada S; Nguyen AM; Wan S; Perini RF; Rhoda Molife L; Atkins MB; Powles T
Eur Urol; 2022 Oct; 82(4):427-439. PubMed ID: 35843776
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.
Eto M; Takagi T; Kimura G; Fukasawa S; Tamada S; Miura Y; Oya M; Sassa N; Anai S; Nozawa M; Sakai H; Perini R; Yusa W; Ikezawa H; Narita T; Tomita Y
Cancer Med; 2023 Mar; 12(6):6902-6912. PubMed ID: 36457273
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
Chen J; Hu G; Chen Z; Wan X; Tan C; Zeng X; Cheng Z
Clin Drug Investig; 2019 Oct; 39(10):931-938. PubMed ID: 31250401
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Chen X; Xu Z; Wu C; Xie L; Wang P; Liu X
Front Immunol; 2024; 15():1255577. PubMed ID: 38390328
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma.
Zhu J; Zhang T; Wan N; Liang Z; Li J; Chen X; Liang W; Jiang J
Immunotherapy; 2020 Dec; 12(17):1237-1246. PubMed ID: 32878521
[No Abstract] [Full Text] [Related]
28. Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Rha SY; Choueiri TK; Matveev VB; Alyasova A; Hong SH; Gordoa TA; Gurney H; Bjarnason GA; Buchler T; Pedrazzoli P; Takagi T; Park SH; Lee JL; Perini RF; He CS; McKenzie JA; Eto M
Int J Cancer; 2023 Sep; 153(6):1241-1250. PubMed ID: 37294085
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
Numakura K; Muto Y; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
Cancer Med; 2021 Sep; 10(17):5839-5846. PubMed ID: 34313025
[TBL] [Abstract][Full Text] [Related]
30. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.
Bilen MA; Rini BI; Voss MH; Larkin J; Haanen JBAG; Albiges L; Pagliaro LC; Voog EG; Lam ET; Kislov N; McGregor BA; Lalani AA; Huang B; di Pietro A; Krulewicz S; Robbins PB; Choueiri TK
Clin Cancer Res; 2022 Feb; 28(4):738-747. PubMed ID: 34789480
[TBL] [Abstract][Full Text] [Related]
31. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
[No Abstract] [Full Text] [Related]
33. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
Choueiri TK; Motzer RJ; Rini BI; Haanen J; Campbell MT; Venugopal B; Kollmannsberger C; Gravis-Mescam G; Uemura M; Lee JL; Grimm MO; Gurney H; Schmidinger M; Larkin J; Atkins MB; Pal SK; Wang J; Mariani M; Krishnaswami S; Cislo P; Chudnovsky A; Fowst C; Huang B; di Pietro A; Albiges L
Ann Oncol; 2020 Aug; 31(8):1030-1039. PubMed ID: 32339648
[TBL] [Abstract][Full Text] [Related]
34. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
[TBL] [Abstract][Full Text] [Related]
35. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
[TBL] [Abstract][Full Text] [Related]
36. Combination Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Alam MU; Jazayeri SB; Gautam S; Norez D; Kumar J; Tanneru K; Nguyen S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
Am J Clin Oncol; 2020 Jul; 43(7):477-483. PubMed ID: 32251121
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis.
Santoni M; Rizzo A; Mollica V; Rosellini M; Marchetti A; Fragomeno B; Battelli N; Massari F
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):45-51. PubMed ID: 34058953
[TBL] [Abstract][Full Text] [Related]
38. Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
Rini BI; Atkins MB; Plimack ER; Soulières D; McDermott RS; Bedke J; Tartas S; Alekseev B; Melichar B; Shparyk Y; Kondoh C; Langiewicz P; Wood LA; Hammers H; Silber CG; Haber B; Jensen E; Chen M; Powles T
Eur Urol Oncol; 2022 Apr; 5(2):225-234. PubMed ID: 34244116
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.
Choueiri TK; Larkin J; Pal S; Motzer RJ; Rini BI; Venugopal B; Alekseev B; Miyake H; Gravis G; Bilen MA; Hariharan S; Chudnovsky A; Ching KA; Mu XJ; Mariani M; Robbins PB; Huang B; di Pietro A; Albiges L
ESMO Open; 2021 Jun; 6(3):100101. PubMed ID: 33901870
[TBL] [Abstract][Full Text] [Related]
40. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T; Nakano Y; Hongo F; Katano H; Miyagawa T; Ueda K; Azuma H; Nozawa M; Hinata N; Hori J; Otoshi T; Shimizu N; Aizawa M; Osada S; Matsui A; Oya M; Eto M; Tomita Y; Shinohara N; Uemura H
Int J Urol; 2024 Mar; 31(3):265-272. PubMed ID: 38110838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
